Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Indaptus Therapeutics Inc. Common Stock
INDP | US
2.06
USD-0.05
-2.37%
INDP | US
Loading StockChartView...
About Indaptus Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
13/04/2026
Close
2.06
Open
2.10
High
2.15
Low
1.80
Indaptus Therapeutics Inc. a clinical biotechnology company develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma hepatocellular colorectal and pancreatic tumors as well as chronic hepatitis B virus and human immunodeficiency virus infection which is in Phase 2 clinical trial. The company was formerly known as Intec Parent Inc. and changed its name to Indaptus Therapeutics Inc. in August 2021. Indaptus Therapeutics Inc. is headquartered in New York New York.
View LessINDP | US
Risk
113.9
Sharpe
-0.60
Luna's Score
40/100
Recommendation
Sell
Luna says (INDP | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
143.6%1 month
113.9%3 months
106.5%6 months
119.4%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.50
Debt to equity
0.02
Debt to assets
0.02
Ent. to EBITDA
1.03
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-16.48M
MarketCap
21.01M
MarketCap(USD)
21.01M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-127.04
Short ratio
1.54
Short perc.
0.45
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.64
Range1M
0.64
Range3M
2.15
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
2.06
Price X volume
221.76K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.03 | 0.53 | Expensive |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.50 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 106.51 | 72.80 | Riskier |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 21.01M | 3.66B | Emerging |
